Candidate rituximab biosimilar; chimeric IgG1 anti-CD20 monoclonal antibody that depletes CD20+ B cells via ADCC, CDC, and apoptosis, reducing autoantibody production and B–T cell interactions.
Chimeric IgG1 anti-CD20 monoclonal antibody that binds CD20 on B lymphocytes and depletes them via ADCC, complement-dependent cytotoxicity, and apoptosis, thereby reducing autoantibody production and B–T cell interactions (plasma cells largely spared).
NO
INDIRECT
The antibody binds CD20 on B cells; its Fc recruits C1q to trigger complement (CDC) and engages FcγR-expressing effectors for ADCC, killing CD20+ B cells—not cells expressing C1q.
EU-approved brand of rituximab; chimeric IgG1 anti-CD20 monoclonal antibody that depletes CD20+ B cells via ADCC, CDC, and apoptosis, reducing autoantibody production and B–T cell interactions.
Chimeric IgG1 anti-CD20 monoclonal antibody that binds CD20 on pre-B and mature B lymphocytes and depletes them via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis, thereby reducing autoantibody production and B–T cell interactions.
YES
DIRECT
Anti-CD20 IgG1 binds CD20 on B cells and induces Fc-mediated ADCC (NK/macrophages) and complement-dependent lysis; cross-linking can also trigger apoptosis.
EU-approved brand of rituximab; chimeric IgG1 anti-CD20 monoclonal antibody that depletes CD20+ B cells via ADCC, CDC, and apoptosis, reducing autoantibody production and B–T cell interactions.
Chimeric IgG1 anti-CD20 monoclonal antibody that binds CD20 on pre-B and mature B lymphocytes and depletes them via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis, thereby reducing autoantibody production and B–T cell interactions.
NO
INDIRECT
Rituximab binds CD20 on B cells; its Fc engages CD16A on NK cells to mediate ADCC, killing CD20+ targets. CD16A-expressing effector cells are not targeted or killed.
EU-approved brand of rituximab; chimeric IgG1 anti-CD20 monoclonal antibody that depletes CD20+ B cells via ADCC, CDC, and apoptosis, reducing autoantibody production and B–T cell interactions.
Chimeric IgG1 anti-CD20 monoclonal antibody that binds CD20 on pre-B and mature B lymphocytes and depletes them via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis, thereby reducing autoantibody production and B–T cell interactions.
NO
INDIRECT
Rituximab binds CD20 on B cells; its Fc engages Fcγ receptors (including CD32A) on effector cells to mediate ADCC and CDC, killing CD20+ B cells. Cells expressing CD32A are not targeted or killed by the drug.
EU-approved brand of rituximab; chimeric IgG1 anti-CD20 monoclonal antibody that depletes CD20+ B cells via ADCC, CDC, and apoptosis, reducing autoantibody production and B–T cell interactions.
Chimeric IgG1 anti-CD20 monoclonal antibody that binds CD20 on pre-B and mature B lymphocytes and depletes them via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptosis, thereby reducing autoantibody production and B–T cell interactions.
NO
INDIRECT
MabThera binds CD20 on B cells and recruits C1q to its Fc to initiate complement-dependent cytotoxicity against CD20+ cells; cells expressing C1q are not directly targeted or killed.